VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Therapeutically targeting CD138, a define multiple myeloma (MM) antigen, is not yet approved for patients. We here developed and determined the preclinical efficacy of VIS832, a novel therapeutic monoclonal antibody (MoAb) with differentiated CD138 target binding to BB4 that is anti-CD138 MoAb scaff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tengteng, Chaganty, Bharat, Lin, Liang, Xing, Lijie, Ramakrishnan, Boopathy, Wen, Kenneth, Hsieh, Phillip A., Wollacott, Andrew, Viswanathan, Karthik, Adari, Hedy, Cho, Shih-Feng, Li, Yuyin, Chen, Hailin, Yang, Wenjuan, Xu, Yan, An, Gang, Qiu, Lugui, Munshi, Nikhil, Babcock, Gregory, Shriver, Zachary, Myette, James R., Anderson, Kenneth C., Tai, Yu-Tzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643177/
https://www.ncbi.nlm.nih.gov/pubmed/33149123
http://dx.doi.org/10.1038/s41408-020-00378-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643177/
https://www.ncbi.nlm.nih.gov/pubmed/33149123
http://dx.doi.org/10.1038/s41408-020-00378-z

Ejemplares similares